Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention

Complications Associated With Artificial Fertilization Clinical Trial

Official title: Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch

Status Completed

Clinical Trial Summary

The purpose of this study is to assess whether, in GnRH agonist in vitro fertilization (IVF) cycles, where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of cabergoline to the hydroxyethyl starch infusion could decrease OHSS incidence and severity.

Clinical Trial Description

Women undergoing IVF cycles with GnRH agonist protocols, at risk of OHSS (more than 20 follicles observed larger than 12 mm in diameter and/or estradiol levels of 3000-5000 pg/mL).

Slow infusion of 500 ml of 6% HES during follicular aspiration alone or combined with 0.5 mg cabergoline administration for 8 days, starting on the day of hCG administration. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Complications Associated With Artificial Fertilization
• Disorder of Endocrine Ovary
• Ovarian Diseases
• Ovarian Hyperstimulation Syndrome

• NCT number: NCT01530490
• Study type: Interventional
• Source: Hospital de Cruces
• Status: Completed
• Phase: Phase 0
• Start date: August 2007
• Completion date: September 2010